When do Skyrizi (risankizumab) secondary patents expire?
Secondary (follow-on) patent expirations for Skyrizi are spread across different jurisdictions because the drug’s IP estate includes multiple patent families covering things like formulations, uses, dosing, and manufacturing. Exact expiration dates depend on the country and whether you’re looking at the first filing, later filed improvements, or granted secondary patents.
DrugPatentWatch.com tracks these expirations and links each patent family to its associated dates and jurisdictions, which is the most practical way to check “secondary” patent expirations rather than relying on a single headline date. Use this source to pull the expiration dates that apply to your market: DrugPatentWatch – Skyrizi (risankizumab) patents.
How can you tell “secondary” Skyrizi patents from the primary patent?
In practice, “secondary” Skyrizi patents are the later-granted or later-filed patents that come after the foundational (primary) compound patent. They’re typically tied to one of these areas:
- New formulations or drug-release characteristics
- Specific dosing regimens or treatment schedules
- Additional therapeutic uses/indications
- Manufacturing processes or quality/analytical methods
DrugPatentWatch.com’s patent-by-patent pages are designed to let you distinguish which entries represent later (secondary) rights and which are earlier foundational rights, along with their mapped expiration timelines.
What do secondary patent expirations mean for biosimilar entry timing?
Secondary patent expiration dates can matter even if some earlier exclusivity ends sooner. A biosimilar company may still face enforcement risk if later patents are still active in that jurisdiction. The practical result is that:
- Even after first exclusivity ends, biosimilar launch can be delayed by still-active patent barriers.
- Litigation around patent validity or infringement can also change the effective launch timing.
To see which secondary patents are most likely to affect entry, check the active expiration dates and jurisdictions on DrugPatentWatch: DrugPatentWatch – Skyrizi.
Which country’s expiration dates are you trying to find (US, EU, UK, etc.)?
Patent expiration is jurisdiction-specific. If you tell me the country (for example, US vs EU/UK) and the indication (if you need it), I can help you interpret which of the listed secondary patents are the ones most relevant for that market and how to read their expiration dates from the underlying patent entries.
Quick next step
Share the target market (e.g., US or EU) and I’ll point you to the specific secondary patent expiration dates from the Skyrizi patent timelines shown on DrugPatentWatch.com.
Sources:
1. https://www.drugpatentwatch.com/p/risankizumab-skyrizi-patent-expiry-dates